Physician profile
David E Pascoe
NPI 1003038555
$5,398.84
in general payments reported to CMS, 2019-2025
26 companies · $753 in 2025
The $753 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $491 · 2020: $230 · 2021: $860 · 2022: $904 · 2023: $1,111 · 2024: $1,050 · 2025: $753.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,731 · Education: $182.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,731.43 |
| Education | $182.15 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,132.55 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $789.63 | 2019-2025 | |
| Leo Pharma INC. | $471.91 | 2019-2025 | Adbry, Anzupgo |
| Pfizer INC. | $467.27 | 2019-2025 | |
| Amgen INC. | $298.32 | 2020-2025 | Otezla, Otezla |
| Ucb, INC. | $262.06 | 2019-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $246.29 | 2019-2025 | Ilumya |
| Regeneron Healthcare Solutions, INC. | $235.93 | 2021-2024 | Dupixent |
| E.R. Squibb & Sons, L.L.C. | $208.62 | 2022-2024 | Sotyktu |
| Genzyme Corporation | $201.33 | 2020-2024 | |
| Janssen Biotech, INC. | $177.56 | 2019-2023 | Tremfya |
| Lilly USA, LLC | $159.41 | 2020-2024 | Ebglyss |
| Incyte Corporation | $140.24 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $117.58 | 2019-2025 | Nemluvio |
| Sanofi-Aventis U.S. LLC | $113.50 | 2021-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biofrontera INC. | $93.47 | 2022-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Arcutis Biotherapeutics, INC. | $52.51 | 2023-2024 | Zoryve |
| Helsinn Therapeutics (U.S.), INC. | $50.42 | 2021-2023 | Valchlor |
| Celgene Corporation | $37.57 | 2019 | |
| Convatec INC. | $31.32 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.42 | 2023 | Spevigo |
| Mayne Pharma Commercial LLC | $23.55 | 2023 | |
| Verrica Pharmaceuticals INC. | $18.58 | 2024 | Ycanth |
| Almirall LLC | $15.71 | 2021 | |
| Merck Sharp & Dohme LLC | $14.98 | 2019 | |
| Kyowa Kirin, INC. | $14.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Pascoe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.